We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01805037
Recruitment Status : Unknown
Verified April 2015 by Adam Petrich, Northwestern University.
Recruitment status was:  Recruiting
First Posted : March 5, 2013
Last Update Posted : April 30, 2015
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Adam Petrich, Northwestern University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : January 2016
  Study Completion Date : No date given